BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees restricted stock units ( RSUs ) covering an aggregate of 30,700 ...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees restricted stock units ( RSUs ) covering an aggregate of 30,700 ...
BioCryst ( BCRX ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Monday, Nov. 3, 2025 at 8:30 a.m. ETChief Executive Officer - John StonehouseContinue reading ...
Top Stocks With Earnings This Week: Joby, IonQ, AMD and More - Palantir Technologies ( NASDAQ:PLTR )
Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday. Here's a look at the names most likely to be on individual investors' radars. CIFR stock is soaring. Watch the real-time price action here.
Ardelyx ( ARDX ) Reports Break-Even Earnings for Q3
Ardelyx (ARDX) delivered earnings and revenue surprises of +100.00% and +10.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Madrigal ( MDGL ) Expected to Beat Earnings Estimates: Should You Buy?
Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HALPER SADEH LLC ENCOURAGES PLYM, HOLX, ATXS, PCH SHAREHOLDERS to Contact the Firm to Discuss Their Rights - Astria Therapeutics ( NASDAQ:ATXS ) , Hologic ( NASDAQ:HOLX )
NEW YORK, Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sotherly Hotels Inc. ( Nasdaq - SOHO ) , Hologic, Inc. ( Nasdaq - HOLX ) , Astria Therapeutics, Inc. ( Nasdaq - ATXS ) , PotlatchDeltic Corporation ( Nasdaq - PCH )
BALA CYNWYD, Pa., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
BioCryst Pharmaceuticals ( BCRX ) Earnings Expected to Grow: Should You Buy?
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology ( ACAAI ) taking place in ...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hologic, Inc. ( Nasdaq - HOLX ) , TrueCar, Inc. ( Nasdaq - TRUE ) , Astria Therapeutics, Inc. ( Nasdaq - ATXS ) , PotlatchDeltic Corporation ( Nasdaq - PCH )
BALA CYNWYD, Pa., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
BioCryst to Report Third Quarter 2025 Financial Results on November 3 - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the company will report its third quarter 2025 financial results on Monday, November 3, 2025. BioCryst management will host a conference call and webcast ...
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders - Astria Therapeutics ( NASDAQ:ATXS ) , Akero Therapeutics ( NASDAQ:AKRO )
NEW YORK, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TrueCar, Inc. ( Nasdaq - TRUE ) , Astria Therapeutics, Inc. ( Nasdaq - ATXS ) , PotlatchDeltic Corporation ( Nasdaq - PCH ) , SWK Holdings Corporation ( Nasdaq - SWKH )
BALA CYNWYD, Pa., Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
BioCryst ( BCRX ) Soars 6.1%: Is Further Upside Left in the Stock?
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.
Teladoc Health Expands Clarity Platform With Workplace Safety Tool
TDOC enhances its Clarity platform with an AI-driven tool to help hospitals combat rising workplace violence incidents.
Why Is BioCryst Pharmaceuticals Stock Trading Lower Today? - Astria Therapeutics ( NASDAQ:ATXS ) , BioCryst Pharma ( NASDAQ:BCRX )
BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) on Tuesday agreed to acquire Astria Therapeutics, Inc. ( NASDAQ:ATXS ) for a mix of cash and stock. The deal represents an implied value of $13 per Astria share, and approximately $700 million in enterprise value.
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock?
Investors need to pay close attention to BCRX stock based on the movements in the options market lately.
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
- Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE portfolio over the next decade -
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile - Astria Therapeutics ( NASDAQ:ATXS ) , BioCryst Pharma ( NASDAQ:BCRX )
- Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE portfolio over the next decade -
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
- Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio ...
Down 14.3% in 4 Weeks, Here's Why BioCryst ( BCRX ) Looks Ripe for a Turnaround
BioCryst (BCRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the compensation committee of BioCryst's board of directors granted eight newly-hired employees stock options to purchase an aggregate of 115,000 shares, and ...
BioCryst Completes Sale of European ORLADEYO® ( berotralstat ) Business - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., Oct. 01, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( NASDAQ:BCRX ) today announced that it has successfully completed the previously announced sale of its European ORLADEYO business to Neopharmed Gentili.
BioCryst Completes Sale of European ORLADEYO® ( berotralstat ) Business
- Transaction valued at $250 million, with up to $14 million in future milestones ...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the compensation committee of BioCryst's board of directors granted nine newly-hired employees stock options to purchase an aggregate of 36,700 shares, and ...
Why Is Ionis Pharma Stock Gaining Thursday? - Ionis Pharmaceuticals ( NASDAQ:IONS )
Dawnzera cut monthly HAE attacks by 81% vs placebo in Phase 3, with up to 87% reduction after second dose. Patients switching from Takhzyro or Orladeyo saw a 62% lower HAE attack rate with Dawnzera. See the 6X seasonal strategy set to target this fall's biggest opportunities. Details here →
BioCryst to Present at Upcoming Investor Conference - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September 4, 2025, at 9:45 a.m. ET.
BioCryst to Present at Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., Aug. 21, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the company plans to present at the Cantor Global Healthcare Conference in New York on Thursday, September 4, 2025, at 9:45 a.m. ET.
Are Options Traders Betting on a Big Move in BCRX Stock?
Investors need to pay close attention to BioCryst Pharmaceuticals stock based on the movements in the options market lately.
BioCryst Announces Departure of Dr. Helen Thackray - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the year.
BioCryst Announces Departure of Dr. Helen Thackray
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the ...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 36,700 shares, and ...
BioCryst Pharmaceuticals ( BCRX ) Surpasses Q2 Earnings and Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of +400.00% and +9.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BioCryst ( BCRX ) Q2 Revenue Jumps 50%
BioCryst Pharmaceuticals ( NASDAQ:BCRX ) , a biotechnology company specializing in oral treatments for rare diseases, released its second quarter earnings on August 4, 2025, reporting its strongest quarterly results to date.
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025.
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025.
Analysts Estimate Esperion Therapeutics ( ESPR ) to Report a Decline in Earnings: What to Look Out for
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals ( BCRX ) Reports Next Week: Wall Street Expects Earnings Growth
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst to Report Second Quarter 2025 Financial Results on August 4
RESEARCH TRIANGLE PARK, N.C., July 21, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, 2025.
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space ( SCS® ) Delivery Platform and Promising Ophthalmology Pipeline
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases ...
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space ( SCS® ) Delivery Platform and Promising Ophthalmology Pipeline - Clearside Biomedical ( NASDAQ:CLSD )
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD -
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., July 09, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their ...
Is BioCryst Pharmaceuticals ( BCRX ) Outperforming Other Medical Stocks This Year?
Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced the appointment of Babar Ghias as chief financial officer ( CFO ) and head of corporate development.
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced the appointment of Babar Ghias as chief financial officer ( CFO ) and head of corporate development.
Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts
ENSG adds Idaho and Texas facilities to its skilled nursing facility and real estate portfolios and earns an opportunity to boost revenues by catering to growing patient volumes.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the compensation committee of BioCryst's board of directors granted eight newly-hired employees restricted stock units ( RSUs ) covering an aggregate of 57,000 ...
